Loading
A phase 3 trial of pembrolizumab in lung cancer, run by University Hospital, Brest, active but no longer recruiting.
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % is a phase 3, randomised interventional study registered as NCT04547504 by University Hospital, Brest, with a registry enrolment figure of 349 participants, started 2020-12-22 and due to reach its primary completion in 2025-12-22. Interventions recorded: Pembrolizumab; Pembrolizumab and Chemotherapy drugs. Conditions listed: Non-small-cell Lung Cancer. Primary outcome: Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR). Lung eligibility wording from the registry: "Histologically or cytologically confirmed NSCLC". Sites: France. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.